Booz Allen, FreshPet, Rocket Pharma Downgraded, While Vail Resorts And FICO Get An Upgrade – Top Wall Street Analyst Calls Today

Wall Street analysts issued a fresh round of ratings changes on Wednesday, including notable upgrades for State Street (STT) and FICO (FICO) and downgrades for Booz Allen (BAH) and Rocket Pharmaceuticals (RCKT), according to TheFly.

Top 3 Upgrades:

State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85. The brokerage sees the company as the biggest beneficiary among trust banks from the recent equity market rebound.

State Street’s stock was up 0.71% in morning trade on Wednesday.

JPMorgan upgraded Vail Resorts’ (MTN) shares to ‘Neutral’ from ‘Underweight,’ keeping the $167 target, citing improved risk-reward at current levels. 

The upgrade comes after the company announced on Tuesday that Rob Katz will return as CEO, effective immediately, replacing Kirsten Lynch, who has served as chief executive for three years.

Vail Resorts’ stock rocketed 14.44% in morning trade on Wednesday.

Baird shifted its outlook on FICO’s shares to a more bullish stance, raising the stock to ‘Outperform’ from ‘Neutral’ but with a lower price target of $1,900, down from $2,021. The brokerage said the stock’s recent sell-off, tied to regulatory risk, creates upside potential.

Fico’s stock traded up 6.3% on Wednesday morning.

Top 3 Downgrades:

Goldman Sachs cut its rating on Booz Allen’s stock to ‘Sell’ from ‘Neutral,’ trimming the price target to $94 from $108, citing limited medium-term growth and downside valuation risk.

Booz Allen’s stock fell 2.24% in morning trade on Wednesday.

Meanwhile, TD Cowen downgraded Freshpet (FRPT) shares to ‘Hold’ from ‘Buy’, maintaining a price target of $96. The brokerage said slowing retail sales growth triggered the call.

Freshpet’s stock was down 4.18% on Wednesday morning. 

Jefferies slashed its rating on Rocket Pharmaceuticals stock to ‘Hold’ from ‘Buy’ and the price target to $2.50 from $29, citing an FDA clinical hold on a key gene therapy trial. 

Rocket Pharmaceutical’s stock was up 3.6% at the start of Wednesday’s session despite the bearish outlook.

The broader market traded in the red as investors watched for Nvidia’s (NVDA) earnings after the closing bell. The SPDR S&P 500 ETF Trust (SPY) fell 0.14%, and the Invesco QQQ Trust (QQQ), which tracks the Nasdaq 100, edged 0.04% lower. The SPDR Dow Jones Industrial Average ETF (DIA) was down 0.1%. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read also: GameStop Stock Declines After First-Ever Bitcoin Buy Worth Half A Billion